Resmed (RSMDF) Cash from Financing Activities (2009 - 2026)

Resmed (RSMDF) has reported Cash from Financing Activities for 18 consecutive years, with -$263.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities fell 60.58% year-over-year to -$263.2 million; the trailing twelve-month figure through Jun 2026 stood at -$1.0 billion (down 66.11% YoY), and the FY2026 full-year result was -$1.0 billion, down 66.11% from the prior year.
• Cash from Financing Activities slipped to -$263.2 million in Q2 2026 per RSMDF's latest filing, from -$255.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $932.9 million in Q4 2022 and bottomed at -$393.3 million in Q2 2024.
• Historically, Cash from Financing Activities has averaged -$128.5 million across 5 years, with a median of -$176.2 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities soared 527.99% in 2022, then tumbled 427.99% in 2023.
• Over 5 years, Cash from Financing Activities stood at $932.9 million in 2022, then tumbled by 125.61% to -$239.0 million in 2023, then soared by 38.26% to -$147.5 million in 2024, then tumbled by 75.11% to -$258.3 million in 2025, then dropped by 1.86% to -$263.2 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$263.2 million, -$255.2 million, and -$258.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.